Akeso announced that the ceremony for Akeso Shanghai Global R&D Center was successfully held at the Zhangjiang headquarters park in Shanghai. The establishment of the Akeso Global R&D Center signifies a crucial step in Akeso's innovative globalization strategy, as it plays a crucial role in driving the company's sustained and high-speed innovative development, enabling the company to enhance its global competitive edge in the field of new drug development. The Akeo Global R&D Center project is situated in Shanghai's Zhangjiang headquarters park (Youchuang Park), spanning an area of 14,454.90 m2, with a total construction area of 66,568.86 m2.

The planned investment for the project is estimated to be RMB 850 million. Leveraging Akeso's internationally advanced drug innovation and development system, the Akeso Global R &D Center will align with the group's R&D strategy and proactively track/lead the latest global research trends. It will focus on cutting-edge areas like gene therapy, cell therapy, neurological diseases, and anti-aging, establishing a leading pipeline for ongoing research while establishing platforms and teams dedicated to tumor microenvironment big data analysis and translational research.

Additionally, the Akeso GlobalR&D Center will utilize China's strengths to connect with global resources, fostering the development of a world-class biopharmaceutical industry cluster in Zhangjiang while facilitating the global expansion of China's domestic innovative drugs.